

Phathom[®]

PHARMACEUTICALS

Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

April 1, 2022

FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 9:30 a.m. ET.

Company management will also participate in one-on-one meetings during the virtual conference which runs from April 11-14, 2022.

To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. The recording will be available for 90 days following the event.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company's website at <http://www.phathompharma.com> and follow the Company on [LinkedIn](#) and [Twitter](#).

CONTACTS

Media Contact:

Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:

Joe Hand
1-877-742-8466
ir@phathompharma.com